Source:http://linkedlifedata.com/resource/pubmed/id/16391822
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-1-4
|
pubmed:abstractText |
Two isoforms of cyclooxygenase (COX) are known, and to date most studies have implicated COX-2 in the development and progression of various human cancers. Increasing evidence suggests that COX-1 may also play a similar role. Indeed, we have recently observed that the dual COX-1/COX-2 inhibitor indomethacin induces apoptosis in human hepatocellular carcinoma (HCC) cell lines more effectively than the selective COX-2 inhibitors, possibly implicating COX-1 in HCC. In this study we investigated the expression of COX-1 in non-tumor and malignant human liver tissues, as well as the effects of the highly selective COX-1 inhibitor SC-560 on cell growth and apoptosis in human HCC cell lines. Expression of COX-1 was detected in nearly all the samples assayed, although with a high variability between non-tumoral (NT) and malignant tissues. The percentage of COX-1 positive cells was significantly higher in the NT tissues than in the tumors (p<0.0001). In well-differentiated HCC COX-1 expression was significantly higher than in the poorly-differentiated tissues (p<0.05). SC-560 showed a dose- and time-dependent inhibitory effect on HCC cell growth. The combination of the COX-1 inhibitor with nimesulide and CAY10404, two selective COX-2 inhibitors, resulted in additive effects on cell growth inhibition. SC-560 also inhibited colony formation in soft agar and induced apoptosis in HCC cells in a dose-dependent manner. Moreover, SC-560 decreased the levels of the anti-apoptotic proteins survivin and XIAP and activated caspase-3 and -7 in a dose- and time-dependent fashion. In conclusion, we report for the first time that the selective COX-1 inhibitor SC-560 exhibits anti-tumor and apoptotic effects in human HCC cells. Overall, our previous and present results suggest that both COX-1 and COX-2 inhibitors may have potential therapeutic implications in HCC patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/SC 560
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1107-3756
|
pubmed:author |
pubmed-author:AzzolinaAntoninaA,
pubmed-author:CervelloMelchiorreM,
pubmed-author:CusimanoAntonellaA,
pubmed-author:D'AlessandroNataleN,
pubmed-author:FlorenaAda MariaAM,
pubmed-author:FoderàDanielaD,
pubmed-author:LampiasiNadiaN,
pubmed-author:MinerviniMarta IdaMI,
pubmed-author:MontaltoGiuseppeG,
pubmed-author:NotarbartoloMonicaM,
pubmed-author:TripodoClaudioC
|
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
245-52
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16391822-Aged,
pubmed-meshheading:16391822-Apoptosis,
pubmed-meshheading:16391822-Carcinoma, Hepatocellular,
pubmed-meshheading:16391822-Cell Line, Tumor,
pubmed-meshheading:16391822-Cell Proliferation,
pubmed-meshheading:16391822-Cyclooxygenase 1,
pubmed-meshheading:16391822-Cyclooxygenase 2,
pubmed-meshheading:16391822-Cyclooxygenase Inhibitors,
pubmed-meshheading:16391822-Female,
pubmed-meshheading:16391822-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:16391822-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16391822-Humans,
pubmed-meshheading:16391822-Immunohistochemistry,
pubmed-meshheading:16391822-Male,
pubmed-meshheading:16391822-Middle Aged,
pubmed-meshheading:16391822-Pyrazoles,
pubmed-meshheading:16391822-RNA, Messenger
|
pubmed:year |
2006
|
pubmed:articleTitle |
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
|
pubmed:affiliation |
Istituto di Biomedicina e Immunologia Molecolare 'Alberto Monroy, C.N.R., Palermo, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|